Lineage Cell Therapeutics, Inc. Common Stock (LCTX)
Cost of Revenue
$187.00K
Quarterly · Period ending: · USD
LCTX Cost of Revenue
Latest reported$187.00Kperiod ending
Latest reported$187.00Kperiod ending
LCTX Quarterly Cost of Revenue ($100.00K → $187.00K)
Quarterly cost of revenue
High-resolution chart · PNG
LCTX cost of revenue history
Quarterly · USD. Dates are reporting period ends; fiscal years can differ from calendar years.
| Period ending | Cost of Revenue (USD) |
|---|---|
| 187,000 | |
| 188,000 | |
| 66,000 | |
| 5,000 | |
| 39,000 | |
| 36,000 | |
| 154,000 | |
| 38,000 | |
| 44,000 | |
| 273,000 | |
| 431,000 | |
| 169,000 | |
| 127,000 | |
| 119,000 | |
| 102,000 | |
| 235,000 | |
| 215,000 | |
| 176,000 | |
| 204,000 | |
| 985,000 | |
| 125,000 | |
| 112,000 | |
| 114,000 | |
| 102,000 | |
| 75,000 | |
| 94,000 | |
| 123,000 | |
| 114,000 | |
| 107,000 | |
| 68,000 | |
| 52,000 | |
| 35,000 | |
| 106,000 | |
| 109,000 | |
| 54,000 | |
| 52,000 | |
| 5,000 | |
| 57,000 | |
| 20,000 | |
| 58,000 | |
| 95,000 | |
| 225,000 | |
| 150,000 | |
| 432,000 | |
| 260,000 | |
| 264,167 | |
| 222,972 | |
| 230,901 | |
| 251,265 | |
| 131,914 | |
| 222,422 | |
| 206,678 | |
| 180,811 | |
| 182,749 | |
| 160,355 | |
| 169,734 | |
| 83,918 | |
| 20,268 | |
| 0 | |
| 18,516 | |
| 24,816 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 |